Biotek-snakken — Februar 2023
-
-
Andre herinde der har Calliditas? Og som har sat sig ind i casen?
Børsværdi på ca 6 mia. SEK, og i færd med at lancere lægemiddel mod en nyresygdom. De slap R2022 i torsdags, og guider selv et salg (ikke overskud) på 1,3 mia sek i 2023 - som jeg læser deres børsmeddelelse. Men hverken en hej til svensk eller beregninger af fremtidig værdi, så søger input.
-
Penser Bank - kender ikke deres troværdighed - har lavet en note. Og der guider de en pæn kursstigning fra de nuværende ca. 100 SEK. Men de nævnet også et studie i marts, som de mener får afgørende betydning for kursen. Igen, er her nogen der er godt unde i casen?
-
3 Biotech Stocks To Watch Ahead Of March 2023 https://www.proinvestor.com/investornyt/946791/3-biotech-stocks-to-watch-ahead-of-march-2023
-
Biogen Says BLA For Lecanemab Gets Priority Review By NMPA In China https://www.proinvestor.com/investornyt/947553/biogen-says-bla-for-lecanemab-gets-priority-review-by-nmpa-in-china
-
Biotech Stocks Facing FDA Decision In March 2023 https://www.proinvestor.com/investornyt/947570/biotech-stocks-facing-fda-decision-in-march-2023
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind